Načítá se...

Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements

In many phase II trials in solid tumours, patients are assessed using endpoints based on the Response Evaluation Criteria in Solid Tumours (RECIST) scale. Often, analyses are based on the response rate. This is the proportion of patients who have an observed tumour shrinkage above a predefined level...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Stat Med
Hlavní autoři: Lin, Chien‐Ju, Wason, James M.S.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2017
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5724692/
https://ncbi.nlm.nih.gov/pubmed/28850689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/sim.7453
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!